Increased disease due to haemophilus influenzae type b: Population-based surveillance in Eastern Gambia, 2008-2013

Pediatric Infectious Disease Journal

Volumn 34, Issue 5, 2015, Pages e107-e112

  Mackenzie, Grant A ^a,b   Ikumapayi, Usman N A ^a   Scott, Susana ^a   Idoko, Olubukola ^a   Odutola, Aderonke ^a   Ndiaye, Malick ^a   Sahito, Shah M ^a   Osuorah, Chidiebereh D ^a   Manjang, Ahmed ^a   Jarju, Sheikh ^a   Bojang, Abdoulie ^a   Roca, Anna ^a   Secka, Ousman ^a   Zaman, Akram ^a   Ceesay, Lamin ^a   Lowe Jallow, Yamundow ^c   Sambou, Sana ^c   Jasseh, Momodou ^a   Antonio, Martin ^a   Greenwood, Brian ^d   Kampmann, Beate ^a   Mulholland, Kim ^b,d   Corrah, Tumani ^a   Howie, Stephen R C ^a   more..

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c Gambia Government   (Gambia)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

conjugate Haemophilus influenzae type b vaccine; Haemophilus influenza; incidence; surveillance

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G ANTIBODY; HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE VACCINE; HAEMOPHILUS VACCINE; VIRUS ANTIBODY;

ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; CHILD; DISEASE SURVEILLANCE; GAMBIA; GROUPS BY AGE; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS MENINGITIS; HUMAN; IMMUNIZATION; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MORBIDITY; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; SEPSIS; SEROLOGY; SEROTYPING; VACCINATION; VACCINE FAILURE; ADOLESCENT; ADULT; BACTERIAL CAPSULE; BLOOD; HAEMOPHILUS INFECTIONS; HEALTH SURVEY; IMMUNOLOGY; STATISTICS AND NUMERICAL DATA; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; BACTERIAL CAPSULES; CHILD; CHILD, PRESCHOOL; GAMBIA; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION; INCIDENCE; POPULATION SURVEILLANCE; YOUNG ADULT;

EID: 84937427653     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000645     Document Type: Article

References (29)

1. Watt JP, Wolfson LJ, O'Brien KL, et al. Hib and Pneumococcal Global Burden of Disease Study Team Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet. 2009; 374: 903-911
2. Scott S, Altanseseg D, Sodbayer D, et al. Impact of Haemophilus influenzae Type b conjugate vaccine in Mongolia: prospective population-based surveillance, 2002-2010. J Pediatr. 2013; 163(1 Suppl): S8-S11
3. Sultana NK, Saha SK, Al-Emran HM, et al. Impact of introduction of the Haemophilus influenzae type b conjugate vaccine into childhood immunization on meningitis in Bangladeshi infants. J Pediatr. 2013; 163(1 Suppl): S73-S78
4. Khowaja AR, Mohiuddin S, Cohen AL, et al. Pakistan Hib Vaccine Study Group Effectiveness of Haemophilus influenzae type b conjugate vaccine on radiologically-confirmed pneumonia in young children in Pakistan. J Pediatr. 2013; 163(1 Suppl): S79-S85.e1
5. Cowgill KD, Ndiritu M, Nyiro J, et al. Effectiveness of Haemophilus influenzae type b Conjugate vaccine introduction into routine childhood immunization in Kenya. JAMA. 2006; 296: 671-678
6. Sow SO, Tapia MD, Diallo S, et al. Haemophilus influenzae Type B conjugate vaccine introduction in Mali: impact on disease burden and serologic correlate of protection. Am J Trop Med Hyg. 2009; 80: 1033-1038
7. Sigaúque B, Vubil D, Sozinho A, et al. Haemophilus influenzae type b disease among children in rural Mozambique: impact of vaccine introduction. J Pediatr. 2013; 163(1 Suppl): S19-S24
8. A degbola RA, Secka O, Lahai G, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet. 2005; 366: 144-150
9. Howie SR, Oluwalana C, Secka O, et al. The effectiveness of conjugate Haemophilus influenzae type B vaccine in The Gambia 14 years after introduction. Clin Infect Dis. 2013; 57: 1527-1534
10. Mackenzie GA, Plumb ID, Sambou S, et al. Monitoring the introduction of pneumococcal conjugate vaccines into West Africa: design and implementation of a population-based surveillance system. PLoS Med. 2012; 9: e1001161
11. A degbola RA, Falade AG , Sam BE, et al. The etiology of pneumonia in malnourished and well-nourished Gambian children. Pediatr Infect Dis J. 1994; 13: 975-982
12. World Health Organisation. WHO Manual: Laboratory Methods for the Diagnosis of Meningitis Caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. Geneva: WHO/Immunisation Vaccines & Biologicals, 2011
13. Sow SO, Okoko BJ, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med. 2011; 364: 2293-2304
14. Heath PT, Booy R, Azzopardi HJ, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA. 2000; 284: 2334-2340
15. L adhani S, Heath PT, Slack MP, et al. Participants of the European Union Invasive Bacterial Infections Surveillance Network Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes. Clin Microbiol Infect. 2010; 16: 948-954
16. A degbola RA, Mulholland EK, Falade AG , et al. Haemophilus influenzae type b disease in the western region of The Gambia: background surveillance for a vaccine efficacy trial. Ann Trop Paediatr. 1996; 16: 103-111
17. N ational AIDS Control Programme. Republic of The Gambia, HIV Sentinel Surveillance Report 2011. Banjul: Ministry of Health & Social Welfare, 2012
18. Bar-On ES, Goldberg E, Fraser A, et al. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Cochrane Database Syst Rev, 2009: CD005530
19. Daza P, Banda R, Misoya K, et al. The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine. 2006; 24: 6232-6239
20. L ee EH, Lewis RF, Makumbi I, et al. Haemophilus influenzae type b conjugate vaccine is highly effective in the Ugandan routine immunization program: a case-control study. Trop Med Int Health. 2008; 13: 495-502
21. L ee EH, Corcino M, Moore A, et al. Impact of Haemophilus influenzae type b conjugate vaccine on bacterial meningitis in the Dominican Republic. Rev Panam Salud Publica. 2008; 24: 161-168
22. Scott JA, Berkley JA, Mwangi I, et al. Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet. 2011; 378: 1316-1323
23. Odutola A, Antonio M, Owolabi O, et al. Comparison of the prevalence of common bacterial pathogens in the oropharynx and nasopharynx of gambian infants. PLoS One. 2013; 8: e75558
24. Fernandez J, Levine OS, Sanchez J, et al. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration. J Infect Dis. 2000; 182: 1553-1556
25. Trotter CL, Ramsay ME, Slack MP. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health. 2003; 6: 55-58
26. Oh SY, Griffiths D, John T, et al. School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom. J Infect Dis. 2008; 197: 1275-1281
27. Watt JP, Chen S, Santosham M. Haemophilus influenzae type b conjugate vaccine: review of observational data on long term vaccine impact to inform recommendations for vaccine schedules. Geneva: World Health Organisation, 2013
28. von Gottberg A, Cohen C, Whitelaw A, et al. Group for Enteric, Respiratory, Meningeal Disease Surveillance in South Africa (GERMS-SA) Invasive disease due to Haemophilus influenzae serotype b ten years after routine vaccination, South Africa, 2003-2009. Vaccine. 2012; 30: 565-571
29. Ulanova M, Tsang RS. Haemophilus influenzae serotype a as a cause of serious invasive infections. Lancet Infect Dis. 2014; 14: 70-82